Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study. Gabrielsen E, Wilsgaard T, Frydenberg H, Lofterod T, et al. Breast Cancer Res Treat 2025 Jul 22. doi: 10.1007/s10549-025-07786.

Read + Share

Amedeo Smart

Independent Medical Education

Gabrielsen E, Wilsgaard T, Frydenberg H, Lofterod T, et al. Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study. Breast Cancer Res Treat 2025 Jul 22. doi: 10.1007/s10549-025-07786.
PMID: 40694191